Apply for the Sunrise Alzheimer's Disease study
A clinical trial near you is evaluating an investigational medication to determine if it is safe and effective in reducing agitation symptoms in patients with Alzheimer’s Disease. Call now to see if you may qualify: +1 (646-440-0560).
Joining a clinical trial may provide options.
Potential to advance medical research for Alzheimer’s Disease.
You may get reimbursed for study-required travel.
What is the purpose of the study?
Agitation, among other symptoms associated with Alzheimer's Disease, can be difficult to manage. This clinical trial, Sunrise, is investigating a study medication to determine if it is safe and effective in reducing agitation symptoms in patients with Alzheimer's Disease.
Download a PDF of the study details.
How to See If Someone Qualifies
See If They May Qualify
Complete a short (<10 min) questionnaire to see if someone you know may be eligible for this study. The information you provide is securely stored and encrypted under HIPAA.
Speak to a Nurse Enrollment Specialist
If someone you know may qualify, you'll schedule a ~30 minute call with a nurse at a time that's convenient. The nurse will address any questions and confirm the patient’s possible eligibility.
Schedule with the Study Doctor
Based on the call and medical history, if a patient is eligible and interested in participating, they’ll be connected with a nearby research site for a possible in-person screening visit.
What to Expect In The Study
Screening (4 weeks) A potential research volunteer will have the opportunity to review the consent document fully to make an educated decision about whether to participate in the trial. Upon consent, the study doctor will perform assessments to confirm that a patient is eligible to participate. Enrolled participants will be randomly assigned either the investigational medication or the placebo.
Study Treatment Period (6 weeks) The study medication being investigated is an oral medication taken every night to see if it potentially reduces agitation symptoms in individuals with Alzheimer's Disease. To monitor safety and study progress, certain study visits will include: collecting medical history information, physician exams, behavioral / psychiatric questionnaires, blood draws, and electrocardiograms (ECGs).
Follow-up (2 weeks) After treatment ends, the study doctor will continue to follow up with the participant. During the last visit of the follow-up period, the participant's safety will be thoroughly monitored and evaluated.
There are 7 total study visits, 6 in person and 1 remote. Of the 6 in person visits, 2 can also be conducted remotely if preferred.
The 7 study visits will be scheduled over a period of about 12 weeks.
1x / night
The study medication is an oral medication that will be taken once daily at bedtime.